Subscribe for the latest consumer trends, trade news, nutrition science and regulatory updates in the supplement industry!
Join 37,000+ members. Yes, it's completely free.
Enzymotec Gains Additional Funding
February 2, 2009
1 Min Read
MIGDAL HAEMEQ, Israel—Enzymotec announced it completed a Series B1 investment round, raising $11 million, and is finalizing a $7 million line of credit from a bank in Israel. According to Ariel Katz, president and CEO of Enzymotec, the funding will enable the company to complete construction on its new plant, which offers increased capacity and wider R&D capabilities.
You May Also Like